Is Mankind Pharma overvalued or undervalued?

Jul 06 2025 08:01 AM IST
share
Share Via
As of July 4, 2025, Mankind Pharma is considered very expensive with a PE ratio of 50.59, significantly higher than its peers like Sun Pharma and Cipla, and despite a 12.3% return over the past year, it has declined 15.24% year-to-date, underperforming the Sensex's 6.77% gain.
As of 4 July 2025, Mankind Pharma's valuation grade has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently overvalued, with a PE ratio of 50.59, an EV to EBITDA of 31.80, and a Price to Book Value of 9.53. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.

In comparison to its peers, Mankind Pharma's valuation stands out as notably high; for instance, Sun Pharma has a PE ratio of 35.2, while Cipla is valued more attractively with a PE of 23.2. This stark contrast highlights Mankind's overvaluation in the current market landscape. Additionally, while Mankind has shown a positive return of 12.3% over the past year, this performance is overshadowed by its year-to-date decline of 15.24%, contrasting with the Sensex's gain of 6.77% in the same period.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News